Alyftrek 10-50-125 MG tablet 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FKRJ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,995
Award facts
- Contract value 100% obligated
- $20,995.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at approximately $21K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of ALYFTREK 10-50-125 mg tablets. This delivery order, awarded on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, indicating the contractor competed in unrestricted federal procurement. The order will be performed at the contractor's Park Ridge facility and represents a routine pharmaceutical supply transaction within the contractor's established federal distribution network.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to optimize pharmaceutical sourcing for Department of Defense military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499.999 billion, was awarded on November 13, 2025, with a 30-month base period and three optional 30-month extension periods extending through December 31, 2036. As a regional prime vendor contractor under this program, DMS Pharmaceutical Group supplies a comprehensive range of branded and generic prescription medications, biologics, vaccines, and medical consumables to support recurring DoD medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DR26FKRJ4?
SPE2DR26FKRJ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FKRJ4 worth?
The government has obligated $20,995 on SPE2DR26FKRJ4.
Is contract SPE2DR26FKRJ4 an order under another contract?
Yes. SPE2DR26FKRJ4 is a delivery order under SPE2DR25D9230, an indefinite delivery contract.
Was contract SPE2DR26FKRJ4 competed?
The extent of competition for SPE2DR26FKRJ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award